Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 12, 2026 | Press Releases

– U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 – – FDA feedback on use of new brilaroxazine formulation in the...

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

Jun 23, 2026 | Press Releases

– The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at VirtualInvestorConferences.com -CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE)...

Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

May 18, 2026 | Press Releases

CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to...

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026 | Press Releases

– Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 – – FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future...

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

Apr 23, 2026 | Press Releases

CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek...